Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAG Adagene	$1.44 +0.3%	$1.72	$1.33 ▼ $3.58	$67.60M	0.61	60,451 shs	4,222 shs
CABA Cabaletta Bio	$1.29 -1.5%	$1.51	$0.99 ▼ $13.50	$65.46M	2.44	1.47 million shs	143,901 shs
GLYC GlycoMimetics	$0.25 -3.6%	$0.24	$0.14 ▼ $1.93	$16.19M	1.74	6.72 million shs	152,237 shs
IZTC Invizyne Technologies	$11.21 +4.5%	$13.43	$8.50 ▼ $23.00	$70.09M	N/A	37,647 shs	7,087 shs

Free Today: Your Guide to Smarter Options Trades

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAG Adagene	+0.35%	-8.06%	-8.36%	-23.80%	-40.38%
CABA Cabaletta Bio	+3.15%	+11.97%	-15.48%	-45.42%	-88.10%
GLYC GlycoMimetics	-0.19%	+18.41%	+19.39%	+3.29%	-84.12%
IZTC Invizyne Technologies	0.00%	-1.01%	+7.41%	-25.59%	+1,072,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADAG Adagene	2.7856 of 5 stars	3.3	5.0	0.0	0.0	2.1	1.7	0.6
CABA Cabaletta Bio	2.9202 of 5 stars	4.5	3.0	0.0	0.0	2.5	0.0	0.6
GLYC GlycoMimetics	2.1435 of 5 stars	0.0	5.0	0.0	4.6	2.6	1.7	0.0
IZTC Invizyne Technologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAG Adagene	2.50	Moderate Buy	$8.00	457.49% Upside
CABA Cabaletta Bio	3.00	Buy	$21.00	1,527.91% Upside
GLYC GlycoMimetics	2.25	Hold	N/A	N/A
IZTC Invizyne Technologies	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest GLYC, ADAG, IZTC, and CABA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/3/2025	ADAG Adagene	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
4/1/2025	CABA Cabaletta Bio	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$6.00 ➝ $3.00
4/1/2025	CABA Cabaletta Bio	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$10.00 ➝ $7.00
4/1/2025	CABA Cabaletta Bio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
4/1/2025	CABA Cabaletta Bio	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$30.00 ➝ $22.00
4/1/2025	CABA Cabaletta Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00
3/21/2025	GLYC GlycoMimetics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight
2/18/2025	CABA Cabaletta Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00
1/31/2025	ADAG Adagene	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight

(Data available from 4/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAG Adagene	$103.20K	655.04	N/A	N/A	$1.61 per share	0.89
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	$5.51 per share	N/A
GLYC GlycoMimetics	$10K	1,619.30	N/A	N/A	$0.08 per share	3.14
IZTC Invizyne Technologies	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAG Adagene	-$18.95M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
CABA Cabaletta Bio	-$67.68M	-$2.34	N/A	N/A	N/A	N/A	-50.10%	-45.49%	5/21/2025 (Estimated)
GLYC GlycoMimetics	-$37.88M	-$0.59	N/A	N/A	N/A	N/A	-230.74%	-177.39%	5/8/2025 (Estimated)
IZTC Invizyne Technologies	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest GLYC, ADAG, IZTC, and CABA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/21/2025	Q1 2025	CABA Cabaletta Bio	-$0.67	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	GLYC GlycoMimetics	-$0.05	N/A	N/A	N/A	N/A	N/A
3/31/2025	Q4 2024	CABA Cabaletta Bio	-$0.65	-$0.65	N/A	-$0.65	N/A	N/A
2/13/2025	Q4 2024	GLYC GlycoMimetics	-$0.16	-$0.11	+$0.05	-$0.11	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAG Adagene	N/A	N/A	N/A	N/A	N/A
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	N/A
GLYC GlycoMimetics	N/A	N/A	N/A	N/A	N/A
IZTC Invizyne Technologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAG Adagene	0.08	2.50	N/A
CABA Cabaletta Bio	N/A	8.11	8.11
GLYC GlycoMimetics	N/A	1.92	1.92
IZTC Invizyne Technologies	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAG Adagene	9.51%
CABA Cabaletta Bio	N/A
GLYC GlycoMimetics	75.19%
IZTC Invizyne Technologies	N/A

Insider Ownership

Company	Insider Ownership
ADAG Adagene	21.20%
CABA Cabaletta Bio	9.88%
GLYC GlycoMimetics	8.70%
IZTC Invizyne Technologies	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAG Adagene	260	47.11 million	34.89 million	Not Optionable
CABA Cabaletta Bio	50	50.74 million	44.05 million	Optionable
GLYC GlycoMimetics	50	64.51 million	58.90 million	Optionable
IZTC Invizyne Technologies	N/A	6.25 million	N/A	N/A

GLYC, ADAG, IZTC, and CABA Headlines

Recent News About These Companies

iTeos Therapeutics (NASDAQ:ITOS) & Invizyne Technologies (NASDAQ:IZTC) Financial Analysis

April 22, 2025 | americanbankingnews.com

Invizyne Technologies (NASDAQ:IZTC) Shares Down 5.4% - Time to Sell?

April 20, 2025 | marketbeat.com

Institutional investors own a significant stake of 42% in Invizyne Technologies, Inc. (NASDAQ:IZTC)

February 13, 2025 | uk.finance.yahoo.com

What’s in a Name: Out with Invizyne, In with eXoZymes

February 12, 2025 | genengnews.com

Invizyne Technologies rebrands as eXoZymes with new ticker EXOZ

February 11, 2025 | msn.com

Invizyne announces corporate name change to eXoZymes

February 11, 2025 | markets.businessinsider.com

Why Invizyne Technologies, Inc.’s (IZTC) Stock Is Up 12.35%

February 5, 2025 | aaii.com

Why Invizyne Technologies, Inc.’s (IZTC) Stock Is Up 10.33%

January 30, 2025 | aaii.com

Invizyne technologies CEO Michael Heltzen buys $20,345 in stock

January 21, 2025 | msn.com

Invizyne Technologies Inc trading resumes

January 1, 2025 | markets.businessinsider.com

Invizyne Technologies Inc trading halted, volatility trading pause

January 1, 2025 | markets.businessinsider.com

Michael Heltzen Buys 1,984 Shares of Invizyne Technologies Inc. (NASDAQ:IZTC) Stock

November 20, 2024 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLYC, ADAG, IZTC, and CABA Company Descriptions

Adagene NASDAQ:ADAG

$1.44 +0.01 (+0.35%)

As of 11:28 AM Eastern

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Cabaletta Bio NASDAQ:CABA

$1.29 -0.02 (-1.53%)

As of 11:41 AM Eastern

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

GlycoMimetics NASDAQ:GLYC

$0.25 -0.01 (-3.65%)

As of 11:36 AM Eastern

GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

Invizyne Technologies NASDAQ:IZTC

$11.21 +0.48 (+4.47%)

As of 04/28/2025

Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time